home / stock / otlk / otlk quote
Last: | $8.43 |
---|---|
Change Percent: | -0.37% |
Open: | $8.22 |
Close: | $8.43 |
High: | $8.5 |
Low: | $8.135 |
Volume: | 120,338 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.43 | $8.22 | $8.43 | $8.5 | $8.135 | 120,338 | 04-26-2024 |
$8.19 | $8.14 | $8.19 | $8.37 | $7.85 | 150,771 | 04-25-2024 |
$8.2 | $8.29 | $8.2 | $8.66 | $8 | 239,635 | 04-24-2024 |
$8.2 | $8.21 | $8.2 | $8.44 | $8.15 | 151,631 | 04-23-2024 |
$8.09 | $8.27 | $8.09 | $8.365 | $7.8 | 210,765 | 04-22-2024 |
$8.17 | $8.28 | $8.17 | $8.63 | $8 | 271,784 | 04-19-2024 |
$8.29 | $8.79 | $8.29 | $8.835 | $8.1208 | 234,621 | 04-18-2024 |
$8.61 | $8.93 | $8.61 | $9.26 | $8.53 | 418,152 | 04-17-2024 |
$8.75 | $8.54 | $8.75 | $9.0399 | $8.54 | 136,801 | 04-16-2024 |
$8.62 | $8.5 | $8.62 | $8.79 | $8.44 | 234,921 | 04-15-2024 |
$8.7 | $9.03 | $8.7 | $9.19 | $8.6101 | 267,111 | 04-12-2024 |
$9.04 | $9.09 | $9.04 | $9.34 | $8.75 | 394,021 | 04-11-2024 |
$8.99 | $9.06 | $8.99 | $9.15 | $8.55 | 503,035 | 04-10-2024 |
$9.26 | $9.35 | $9.26 | $9.98 | $9.03 | 359,778 | 04-09-2024 |
$9.35 | $9.23 | $9.35 | $9.48 | $8.89 | 248,028 | 04-08-2024 |
$9.26 | $9.5 | $9.26 | $9.61 | $9.0501 | 198,467 | 04-05-2024 |
$9.52 | $9.2 | $9.52 | $9.86 | $8.74 | 895,790 | 04-04-2024 |
$9.12 | $9.78 | $9.12 | $10.21 | $9 | 774,705 | 04-03-2024 |
$9.7 | $10.33 | $9.7 | $10.95 | $8.85 | 1,015,614 | 04-02-2024 |
$10.26 | $12.36 | $10.26 | $12.8499 | $9.95 | 1,185,045 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed...
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...